The Novosanis Grant Program is designed to foster research projects assessing:
- The standardization of urine collection, handling, storage, and sample preparation for cancer biomarker detection with known and commonly applied technologies
- Discovery of new “urinary” biomarkers
- Assay development for extraction methods, downstream analysis and validation
Novosanis intends to provide a research grant of (up to) 25,000€ in support of the most impactful proposal and (up to) 200 Colli-Pee® urine collection devices for use with the project.
In addition to the award value, winner(s) of this challenge will be eligible to receive support from Novosanis’ Product Management, Marketing and/or R&D teams to help validate the concept and/or recruitment campaigns.
The winner will:
- Be selected by the EACR committee including representation from Novosanis
- Present his/her findings during a webinar/event
Applications are now closed. Stay tuned for future grants.
Explanation and program details
Novosanis is offering a research grant exclusive to EACR members to stimulate innovative research in cancer biomarker detection using urine as a sample type. As urine sampling is easy, quick and non-invasive it has the potential to change the way cancer is detected and monitored today. The quality of the urine sample and analytical procedures utilized are critical components to reach this objective.
Urine can not only be used as a liquid biopsy for urogenital tract related cancers such as bladder, prostate, renal, ovarian, endometrial and cervical cancer but also for the detection of thyroid, breast, lung, pancreatic and colorectal cancer. Several biomarker candidates have been identified in urine, in the field of genomics, transcriptomics, proteomics, and metabolomics.
However, collecting a urine sample with a standard urine cup can be awkward, messy and inconvenient for the patient. For this reason, Novosanis developed Colli-Pee®, a device that can be used by both men and women. Colli-Pee® allows for standardized, volumetric collection of the first-void fraction of the urine flow. The device architecture also ensures immediate mixing of urine and preservative for adequate stability, thereby enabling sample storage and transport at room temperature. This allows for home-based collection and large-scale study recruitment.
Introduction
